Takeda Pharmaceutical reports 3.8% jump in underlying revenue for 3 quarters of FY2015: 4 notes

Takeda Pharmaceutical reported strong financials for three quarters of fiscal year 2015, from April to December.

Advertisement

Here are four notes:

1. The company’s underlying revenue increased by 3.8 percent year-to-year, led by strong performance in the U.S. and the emerging markets

2. It also reported an underlying core earnings increase of 1.5 percent year-to-year.

3. Underlying revenue from the gastroenterology market was up by 24.7 percent year-to-year.

4. Based on performance through three quarters, Takeda raised the full-year reported forecast for operating profit to 120 billion yen.

More articles on GI/endoscopy:
DuPage Medical Group acquires Midwest Digestive Disease Specialists: 3 things to know
8 must-reads on colonoscopy
5 things to know about office visit costs prior to screening colonoscopy

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.